GlaxoSmithKline plc (LON:GSK) insider Dominic Redfern acquired 10 shares of the business’s stock in a transaction dated Friday, March 9th. The stock was purchased at an average price of GBX 1,343 ($18.55) per share, with a total value of £134.30 ($185.55).
Dominic Redfern also recently made the following trade(s):
- On Wednesday, January 10th, Dominic Redfern acquired 10 shares of GlaxoSmithKline stock. The stock was purchased at an average price of GBX 1,333 ($18.42) per share, with a total value of £133.30 ($184.17).
Shares of GlaxoSmithKline plc (GSK) traded up GBX 2 ($0.03) during trading on Monday, reaching GBX 1,338 ($18.49). 4,800,000 shares of the company’s stock traded hands, compared to its average volume of 8,990,000. GlaxoSmithKline plc has a twelve month low of GBX 1,235.20 ($17.07) and a twelve month high of GBX 1,724.50 ($23.83). The company has a market capitalization of $66,350.00 and a price-to-earnings ratio of 2,524.53.
A number of equities analysts have recently commented on the stock. Liberum Capital restated a “buy” rating and issued a GBX 1,630 ($22.52) price objective on shares of GlaxoSmithKline in a research report on Thursday. Goldman Sachs Group set a GBX 1,750 ($24.18) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a research report on Friday, March 2nd. HSBC restated a “buy” rating and issued a GBX 1,925 ($26.60) price objective on shares of GlaxoSmithKline in a research report on Tuesday, February 27th. Jefferies Group set a GBX 1,475 ($20.38) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, JPMorgan Chase & Co. set a GBX 1,320 ($18.24) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research report on Monday, February 12th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. GlaxoSmithKline presently has an average rating of “Hold” and an average target price of GBX 1,538.18 ($21.25).
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/12/glaxosmithkline-plc-gsk-insider-dominic-redfern-buys-10-shares.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.